With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...
Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...
Pharmaceutical Technology on MSN
China’s NMPA approves Sanofi’s rare haematologic disease treatments
China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...
China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...
Sanofi secures China approvals for Qfitlia and Cablivi, expanding its rare hematology portfolio with new options for ...
Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...
Alnylam Pharmaceuticals, Inc. ("Alnylam") (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has entered into separate, privately negotiated repurchase agreements with ...
Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...
A forward-looking analysis of how nonfactor therapies are transforming patient quality of life, clinician-patient collaboration, and the broader healthcare ecosystem for hemophilia management. The MHE ...
Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, ...
– Mike Bonney and Carolyn Bertozzi to Depart; Company Appoints Stuart Arbuckle as New Independent Director – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback